Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752922 | 0.80 | RAB9A (0.62) | MEN1KMT2AMAPTMAPK1TP53 | |
| SCHEMBL27040083 | 0.79 | MAPT (0.58) | MEN1KMT2AMAPTMAPK1TP53 | |
| SCHEMBL8024017 | 0.78 | DGAT1 (0.61) | MEN1KMT2AMAPTMAPK1ABCG2 | |
| SCHEMBL20550980 | 0.77 | MAPT (0.75) | MEN1KMT2AMAPTMAPK1TP53 | |
| SCHEMBL30857514 | 0.77 | MAPT (0.75) | MEN1KMT2AMAPTMAPK1TP53 | |
| SCHEMBL180946 | 0.76 | DGAT1 (0.50) | MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL20067339 | 0.76 | MEN1 (0.60) | MEN1KMT2AMAPTMAPK1TP53 | |
| SCHEMBL2541551 | 0.76 | TRPV1 (0.57) | MEN1KMT2AMAPTMAPK1TP53 | |
| SCHEMBL8024061 | 0.75 | MAPT (0.76) | MEN1KMT2AMAPTMAPK1TP53 | |
| SCHEMBL28706653 | 0.75 | MEN1 (0.57) | MEN1KMT2AMAPTMAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | claimed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | claimed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | claimed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | claimed |
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | disclosed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | disclosed |
| US-8524682-B2 | Compositions and methods for inhibiting EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011103016-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100222420-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-09-02 | — | — | US | disclosed |
| US-20090012031-A1 | EZH2 Cancer Markers | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | EZH2, BMI1, EZH1 | MEN1 1330/4885KMT2A 23/4885MAPT 3335/4885 |
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | AHR, ARNT, ARSA | MEN1 4634/4885KMT2A 503/4885MAPT 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.